In a landmark phase 3 trial published in Nature Medicine, Prof. Sherene Loi and colleagues investigated whether immunotherapy can shift the treatment paradigm in high-risk early ER+/HER2− breast cancer.
The study showed that adding nivolumab to standard neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates compared to chemotherapy alone (24.5% vs 13.8%; P = 0.0021). The benefit was particularly pronounced in tumors expressing PD-L1 (44.3% vs 20.2%).
These results highlight the potential of integrating immunotherapy into early treatment strategies for luminal breast cancer, especially in patients with immunologically “hot” tumors.
For more details, access the full article here: https://lnkd.in/e4s2zRbb
Congratulations to Prof. Sherene Loi (Peter MacCallum Cancer Centre, Melbourne) and the global team of investigators on this milestone contribution.
